[1] Lipton A, Steger GG, Figueroa J, et al.  Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy[J]. Clin Cancer Res, 2008, 14(20): 6690-6696.   doi: 10.1158/1078-0432.CCR-07-5234
[2] Even-Sapir E, Metser U, Mishani E, et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT[J]. J Nucl Med, 2006, 47(2): 287-297.
[3] 中华人民共和国卫生部医政司.  核医学诊断与治疗规范[J]. 北京: 科学出版社, 1997, : 292-295.   doi: 10.3321/j.issn:1671-167X.1997.04.002
[4] Wong J, Hird A, Kirou-Mauro A, et al.  Quality of life in brain metastases radiation trials: a literature review[J]. Curr Oncol, 2008, 15(5): 25-45.   doi: 10.3747/co.v15i5.290
[5] 赵卫威, 解鹏, 邓候富.  89Sr治疗前列腺癌骨转移的研究进展[J]. 中华男科学杂志, 2010, 16(3): 269-272.
[6] 青春, 邓候富, 贾志云.  放射性核素89Sr治疗骨转移癌的新进展[J]. 国际放射医学核医学杂志, 2007, 31(3): 160-162.   doi: 10.3760/cma.j.issn.1673-4114.2007.03.011
[7] 欧阳伟, 刘金华, 刘伟英.  89SrCl2治疗无骨痛的多发性骨转移瘤的效果[J]. 南方医科大学学报, 2007, 27(3): 390-391.   doi: 10.3321/j.issn:1673-4254.2007.03.045
[8] 张晓红, 王鸿智, 陈正国, 等.  89Sr治疗乳腺癌多发性骨骼转移临床疗效评价[J]. 中国肿瘤临床与康复, 2008, 15(3): 227-228.